The inflammatory consequences of psychologic stress: Relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II

Medical Hypotheses

Volumn 67, Issue 4, 2006, Pages 879-891

  Black, Paul H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ACUTE PHASE PROTEIN; ADIPOCYTOKINE; ADRENALIN; ANGIOTENSIN II; CATECHOLAMINE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; FAT; FATTY ACID; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEPTIN; LIPOPROTEIN LIPASE; NORADRENALIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADIPOCYTE; ADRENERGIC SYSTEM; APPETITE; ARTICLE; ATHEROSCLEROSIS; BLOOD; BODY FAT DISTRIBUTION; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL VOLUME; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; CULTURAL FACTOR; CYTOKINE PRODUCTION; DISEASE MODEL; EFFERENT NERVE; ENERGY BALANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD INTAKE; HORMONE ACTION; HOST; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INNATE IMMUNITY; INNERVATION; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LIVER FUNCTION; MACROPHAGE; MEDIATOR; MENTAL STRESS; METABOLIC SYNDROME X; METABOLISM; MOLECULE; NEUROBIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIMATE; PRIORITY JOURNAL; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SIGNAL PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; VASCULARIZATION; VASCULITIS; WEIGHT REDUCTION;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MODELS, IMMUNOLOGICAL; OBESITY; STRESS, PSYCHOLOGICAL;

EID: 33745941592     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.04.008     Document Type: Article

References (95)

1. Black P.H. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 16 6 (2002) 622-653
2. Maier S.F., and Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 105 1 (1998) 83-107
3. Seematter G., Binnert C., Martin J.L., and Tappy L. Relationship between stress, inflammation and metabolism. Curr Opin Clin Nutr Metab Care 7 2 (2004) 169-173
4. McCarty M.F. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 52 5 (1999) 465-477
5. Morimoto A., Watanabe T., Myogin T., and Murakami N. Restraint induced stress elicits acute-phase response in rabbits. Pflugers Arch 410 4-5 (1987) 554-556
6. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18 49 (1999) 6853-6866
7. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 100 4 (2003) 1920-1925
8. Rhen T., and Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. New Engl J Med 353 16 (2005) 1711-1723
9. Ghanim H., Aljada A., Hofmeyer D., Syed T., Mohanty P., and Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110 12 (2004) 1564-1571
10. Black P.H. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 17 5 (2003) 350-364
11. Brindley D.N., and Rolland Y. Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin Sci (Lond) 77 5 (1989) 453-461
12. Kullo I.J., Cassidy A.E., Peyser P.A., Turner S.T., Sheedy P.F., and Bielak L.F. Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. Am J Cardiol 94 12 (2004) 1554-1558
13. Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep 3 Suppl. 1 (2001) S3-S9
14. Pliquett R.U., Fasshauer M., Bluher M., and Paschke R. Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol (2004) 3-4
15. Julius S., and Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken-and-egg' question. J Hypertens 12 5 (1994) 495-502
16. Julius S., Gudbrandsson T., Jamerson K., Tariq S.S., and Andersson O. The hemodynamic link between insulin resistance and hypertension. J Hypertens 9 11 (1991) 983-986
17. Serne E.H., Stehouwer C.D., ter Maaten J.C., ter Wee P.M., Rauwerda J.A., Donker A.J., et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 99 7 (1999) 896-902
18. de Jongh R.T., Serne E.H., Ijzerman R.G., de Vries G., and Stehouwer C.D. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 53 11 (2004) 2873-2882
19. Neutel J.M. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 18 9 (2004) 599-606
20. Mattacks C.A., and Pond C.M. Interactions of noradrenalin and tumour necrosis factor alpha, interleukin 4 and interleukin 6 in the control of lipolysis from adipocytes around lymph nodes. Cytokine 11 5 (1999) 334-346
21. Marz P., Cheng J.G., Gadient R.A., Patterson P.H., Stoyan T., Otten U., et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA 95 6 (1998) 3251-3256
22. Brunner E.J., Hemingway H., Walker B.R., Page M., Clarke P., Juneja M., et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation 106 21 (2002) 2659-2665
23. Kusunoki M., Cooney G.J., Hara T., and Storlien L.H. Amelioration of high-fat feeding-induced insulin resistance in skeletal muscle with the antiglucocorticoid RU486. Diabetes 44 6 (1995) 718-720
24. Green P.G., Janig W., and Levine J.D. Negative feedback neuroendocrine control of inflammatory response in the rat is dependent on the sympathetic postganglionic neuron. J Neurosci 17 9 (1997) 3234-3238
25. Munck A., and Naray-Fejes-Toth A. Glucocorticoids and stress: permissive and suppressive actions. Ann N Y Acad Sci 746 (1994) 115-130
26. Fain J.N., and Garcija-Sainz J.A. Adrenergic regulation of adipocyte metabolism. J Lipid Res 24 8 (1983) 945-966
27. Tomlinson J.W., Moore J., Cooper M.S., Bujalska I., Shahmanesh M., Burt C., et al. Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142 5 (2001) 1982-1989
28. Kotelevtsev Y., Brown R.W., Fleming S., Kenyon C., Edwards C.R., Seckl J.R., et al. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 103 5 (1999) 683-689
29. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202 4 (2005) 517-527
30. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 14 12 (1991) 1132-1143
31. Raikkonen K., Keltikangas-Jarvinen L., Adlercreutz H., and Hautanen A. Psychosocial stress and the insulin resistance syndrome. Metabolism 45 12 (1996) 1533-1538
32. Kahl K.G., Bester M., Greggersen W., Rudolf S., Dibbelt L., Stoeckelhuber B.M., et al. Visceral fat deposition and insulin sensitivity in depressed women with and without comorbid borderline personality disorder. Psychosom Med 67 3 (2005) 407-412
33. Black P.H., and Garbutt L.D. Stress, inflammation and cardiovascular disease. J Psychosom Res 52 1 (2002) 1-23
34. Clement K., Vaisse C., Manning B.S., Basdevant A., Guy-Grand B., Ruiz J., et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. New Engl J Med 333 6 (1995) 352-354
35. Shaw D.I., Hall W.L., and Williams C.M. Metabolic syndrome: what is it and what are the implications. Proc Nutr Soc 64 3 (2005) 349-357
36. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 8 (2004) 764-772
37. Boden G., and Shulman G.I. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 32 Suppl. 3 (2002) 14-23
38. Caglayan E., Blaschke F., Takata Y., and Hsueh W.A. Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 5 2 (2005) 135-142
39. Ghiadoni L., Donald A.E., Cropley M., Mullen M.J., Oakley G., Taylor M., et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 102 20 (2000) 2473-2478
40. Balletshofer B.M., Rittig K., Stock J., Lehn-Stefan A., Overkamp D., Dietz K., et al. Insulin resistant young subjects at risk of accelerated atherosclerosis exhibit a marked reduction in peripheral endothelial function early in life but not differences in intima-media thickness. Atherosclerosis 171 2 (2003) 303-309
41. Das U.N. Metabolic syndrome X: an inflammatory condition?. Curr Hypertens Rep 6 1 (2004) 66-73
42. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., and Connell J.M. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci (Lond) 98 5 (2000) 531-535
43. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106 3 (2002) 286-288
44. Julius S., Jamerson K., Gudbrandsson T., and Schork N. White coat hypertension: a follow-up. Clin Exp Hypertens A 14 1-2 (1992) 45-53
45. Esler M., and Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 35 7 Suppl. 4 (2000) S1-S7
46. Chae C.U., Lee R.T., Rifai N., and Ridker P.M. Blood pressure and inflammation in apparently healthy men. Hypertension 38 3 (2001) 399-403
47. Doo Y.C., Han S.J., Lee J.H., Cho G.Y., Hong K.S., Han K.R., et al. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris. Am J Cardiol 93 5 (2004) 554-558
48. Wassmann S., Stumpf M., Strehlow K., Schmid A., Schieffer B., Bohm M., et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94 4 (2004) 534-541
49. Fernandez-Real J.M., Vayreda M., Richart C., Gutierrez C., Broch M., Vendrell J., et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86 3 (2001) 1154-1159
50. Wheatcroft S.B., Williams I.L., Shah A.M., and Kearney M.T. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 20 4 (2003) 255-268
51. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med 340 2 (1999) 115-126
52. Orr A.W., Sanders J.M., Bevard M., Coleman E., Sarembock I.J., and Schwartz M.A. The subendothelial extracellular matrix modulates NF-kappaB activation by flow: a potential role in atherosclerosis. J Cell Biol 169 1 (2005) 191-202
53. Mullaly S.C., and Kubes P. Toll gates and traffic arteries: from endothelial TLR2 to atherosclerosis. Circ Res 95 7 (2004) 657-659
54. Hingorani A.D., Cross J., Kharbanda R.K., Mullen M.J., Bhagat K., Taylor M., et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102 9 (2000) 994-999
55. Bhagat K., and Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 96 9 (1997) 3042-3047
56. Grekin R.J., Vollmer A.P., and Sider R.S. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 26 1 (1995) 193-198
57. Lutz T.A., Niijima A., and Scharrer E. Intraportal infusion of 2,5-anhydro-d-mannitol increases afferent activity in the common hepatic vagus branch. J Autonom Nerv Sys 61 2 (1996) 204-208
58. Niijima A. Afferent signals from leptin sensors in the white adipose tissue of the epididymis, and their reflex effect in the rat. J Autonom Nerv Syst 73 1 (1998) 19-25
59. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112 12 (2003) 1821-1830
60. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 12 (2003) 1785-1788
61. Lin Y., Rajala M.W., Berger J.P., Moller D.E., Barzilai N., and Scherer P.E. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 276 45 (2001) 42077-42083
62. Engstrom G., Hedblad B., Stavenow L., Lind P., Janzon L., and Lindgarde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 52 8 (2003) 2097-2101
63. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 12 (2003) 1796-1808
64. Werner N., and Nickenig G. From fat fighter to risk factor: the zigzag trek of leptin. Arterioscl Thromb Vasc Biol 24 1 (2004) 7-9
65. Ouchi N., Kihara S., Funahashi T., Matsuzawa Y., and Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14 6 (2003) 561-566
66. Stern M.P. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44 4 (1995) 369-374
67. Dominiczak M.H. Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clin Chem Lab Med 41 9 (2003) 1266-1278
68. Ruderman N., Chisholm D., Pi-Sunyer X., and Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes 47 5 (1998) 699-713
69. Bjorntorp P., and Rosmond R. Hypothalamic origin of the metabolic syndrome X. Ann NY Acad Sci 892 (1999) 297-307
70. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities?. Obes Rev 2 2 (2001) 73-86
71. Wright S.D., Burton C., Hernandez M., Hassing H., Montenegro J., Mundt S., et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 191 8 (2000) 1437-1442
72. Lau D.C., Dhillon B., Yan H., Szmitko P.E., and Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 288 5 (2005) H2031-H2041
73. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscl Thromb Vasc Biol 24 1 (2004) 29-33
74. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., and Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1 2 (2004) e45
75. Zoccali C. Neuropeptide Y as a far-reaching neuromediator: from energy balance and cardiovascular regulation to central integration of weight and bone mass control mechanisms. Implications for human diseases. Curr Opin Nephrol Hypertens 14 1 (2005) 25-32
76. Dallman M.F., Pecoraro N.C., and la Fleur S.E. Chronic stress and comfort foods: self-medication and abdominal obesity. Brain Behav Immun 19 4 (2005) 275-280
77. Lindmark S., Wiklund U., Bjerle P., and Eriksson J.W. Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first-degree relatives of Type 2 diabetes patients and control subjects. Diabet Med 20 5 (2003) 399-405
78. Bouloumie A., Curat C.A., Sengenes C., Lolmede K., Miranville A., and Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 8 4 (2005) 347-354
79. Tannock L.R., O'Brien K.D., Knopp R.H., Retzlaff B., Fish B., Wener M.H., et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 111 23 (2005) 3058-3062
80. Wisse B.E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15 11 (2004) 2792-2800
81. Rahmouni K., and Haynes W.G. Leptin signaling pathways in the central nervous system: interactions between neuropeptide Y and melanocortins. Bioessays 23 12 (2001) 1095-1099
82. Lam T.K., Pocai A., Gutierrez-Juarez R., Obici S., Bryan J., Aguilar-Bryan L., et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med 11 3 (2005) 320-327
83. Troseid M., Lappegard K.T., Claudi T., Damas J.K., Morkrid L., Brendberg R., et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J 25 4 (2004) 349-355
84. Olefsky J., Reaven G.M., and Farquhar J.W. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 53 1 (1974) 64-76
85. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100 5 (1997) 1230-1239
86. Hall J.E., Brands M.W., Dixon W.N., and Smith Jr. M.J. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 22 3 (1993) 292-299
87. Esposito K., Pontillo A., Di Palo C., Giugliano G., Masella M., Marfella R., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289 14 (2003) 1799-1804
88. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 16 (2002) 2067-2072
89. Dandona P., Mohanty P., Ghanim H., Aljada A., Browne R., Hamouda W., et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab 86 1 (2001) 355-362
90. Clement K., Viguerie N., Poitou C., Carette C., Pelloux V., Curat C.A., et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 18 14 (2004) 1657-1669
91. Kelley D.E. Thermodynamics, liposuction, and metabolism. New Engl J Med 350 25 (2004) 2542-2544
92. Ramos E.J., Xu Y., Romanova I., Middleton F., Chen C., Quinn R., et al. Is obesity an inflammatory disease?. Surgery 134 2 (2003) 329-335
93. Karbowska J., and Kochan Z. Effect of DHEA on endocrine functions of adipose tissue, the involvement of PPAR gamma. Biochem Pharmacol 70 2 (2005) 249-257
94. Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 5 3 (2005) 309-322
95. Gould S.J. Darwinism and the expansion of evolutionary theory. Science 216 (1982) 380-387